Progress Life Sciences Pvt. Ltd. is a Sucralfate manufacturer. Exporter Supplier
We are a Sucralfate Manufacturer, Exporter, Supplier, Distributor, Trader and Exporter of High-Quality API, Lornoxicam, Ethyl Oleate, Linagliptin, Bromhexine.
Our main Export in Markets, Africa, Middle East, South, Latin America, Southeast Asia, SAARC, Pakistan and Bangladesh are dealers.
Progress Life Sciences Pvt. Ltd.(PLS) is a professionally managed rapidly evolving company founded by technocrats with a vision to carry out business globally Lornoxicam: INH. This company has been founded by 1st generation entrepreneurs with a strong desire to create a world-class generic pharmaceutical and chemical company.
We are a lean company with skilled, educated & experienced professionals who look after various critical operations on day to day basis and have been successfully able to establish the base for a bigger business platform globally. Our present core focus area remains APIs and intermediates Lornoxicam: INH.
At PLS, we believe that success is defined by the positive impact which we make on the world around us. Since the beginning, our goal has always been to provide access to affordable healthcare solutions to millions of people who are in need.
Over a period of time, PLS has successfully been able to develop new products, gained market approvals, made commercial supplies to customers of repute in both domestic and international markets & have created a basket that will bring in growth for the company and its people. Our Products are being exported to LATAM, Middle East and Asian subcontinents.
Progress Life Sciences Pvt. Ltd is an API distributor. Progress Life Sciences Pvt. Ltd can supply CGMP and/or DMF products, subject to availability and manufacturer requirements. We are a Sucralfate Manufacturer, Exporter, Supplier, Distributor, Trader and Exporter of High-Quality API, Lornoxicam, Ethyl Oleate, Linagliptin, Bromhexine. Progress Life Sciences Pvt. Ltd does not sell or supply APIs or finished dosage products to individual patients, doctors, pharmacies, or any pharmaceutical companies.
Questions? Call our customer API support number +91 22 49781414
For the short-term treatment (up to 8 weeks) of active duodenal ulcer, as well as maintenance therapy for duodenal ulcer patients at the reduced dosage (1 gram twice a day) after healing of acute ulcers. Also used for the short-term treatment of gastric ulcers.
Mode of Action:
Although sucralfate’s mechanism is not entirely understood, there are several factors that most likely contribute to its action. Sucralfate, with its strong negative charge, binds to exposed positively charged proteins at the base of ulcers. In this way, it coats the ulcer and forms a physical barrier that protects the ulcer surface from further injury by acid and pepsin. It directly inhibits pepsin (an enzyme that breaks apart proteins) in the presence of stomach acid and binds bile salts coming from the liver via the bile thus protecting the stomach lining from injury caused by the bile acids. Sucralfate may increase prostaglandin production. Prostaglandins are known to protect the lining of the stomach and may also bind epithelial growth factors and fibroblast growth factors, both of which enhance the growth and repair mechanism of the stomach lining.
Sucralfate is only minimally absorbed from the gastrointestinal tract. The small amounts of the
sulfated disaccharides that are absorbed are excreted primarily in the urine.
Although the mechanism of sucralfate’s ability to accelerate healing of duodenal ulcers remains to be fully defined, it is known that it exerts its effect through a local, rather than systemic, action.
The following observations also appear pertinent:
1. According to studies in human subjects and with animal models of ulcer disease, sucralfate forms an ulcer-adherent complex with proteinaceous exudate at the ulcer site.
2. In vitro, a sucralfate-albumin film provides a barrier to the diffusion of hydrogen ions.
3. In human systems, for ulcer therapy, sucralfate doses inhibit pepsin activity in gastric juice by 32%.
In vitro, sucralfate adsorbs bile salts.
These observations suggest that sucralfate’s antiulcer activity is the result of the formation of an ulcer-adherent complex that covers the ulcer site and protects it against further attack by acid, pepsin, and bile salts.
Acute oral toxicity (LD50) in mice is >8000 mg/kg. There is limited experience in humans with overdosage of sucralfate. Sucralfate is only minimally absorbed from the gastrointestinal tract and thus risks associated with acute overdosage should be minimal. In rare reports describing sucralfate overdose, most patients remained asymptomatic.
Questions? Call our customer API support number
- Office: Progress Life Sciences Pvt. Ltd., Haware Fantasia Business Park, F-17, 1st floor, Sector 30-A, Near Vashi Station, Vashi, Navi Mumbai 400703
- Manufacturing: Progress Life Sciences Pvt. Ltd., J-311,Bhosari MIDC, Pune – 400 026 Maharashtra, India
- +91 22 49781414